FMFatma Abdelhakim Mohamed

Fatma Abdelhakim Mohamed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fatma Abdelhakim Mohamed has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pathophysiology-driven use of natural products in irritable bowel syndrome: a review

    by Fatma Abdelhakim Mohamed, Mennat-Allah M. Hassan, Yara M. Aboulmagd, Kareem A. Attallah, Heba R. Ghaiad, Riham A. El-Shiekh, Mohamed I. Fahmy

    Irritable bowel syndrome (IBS) is a highly prevalent disorder of gut–brain interaction characterized by chronic abdominal pain associated with altered bowel habits, including constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), mixed (IBS-M), and unsubtyped forms. The pathophysiology of IBS is believed to be multifactorial as it involves dysregulation of the gut–brain axis, visceral hypersensitivity, serotonergic imbalance, epithelial barrier dysfunction, immune activation, dysbiosis, bile acid alterations, in addition to psychosocial stressors. These interacting mechanisms are known to be involved in the generation of persistent symptoms as well as the widely reported clinical heterogeneity of the disease. Current management strategies include dietary modification, psychological therapies, microbiota-targeted approaches, and pharmacological agents targeting the prevalent symptom subtype. However, treatment responses remain variable, and many patients seek complementary and natural interventions to alleviate their symptoms. Emerging evidence suggests that natural products may exert therapeutic benefits through anti-inflammatory actions, modulation of serotonergic signaling, improvement of intestinal barrier integrity, microbiota regulation, and neuromodulatory effects. Clinical studies demonstrate that certain natural interventions, particularly peppermint oil, STW 5 (Iberogast), psyllium, and several selected probiotics, can provide modest but clinically meaningful symptom improvement, especially for abdominal pain. Nonetheless, heterogeneity in trial design, short durations, small sample sizes, and limited subtype stratification restrict the strength of the resulting recommendations. This review provides a comprehensive overview of IBS pathophysiology, current treatment strategies, and mechanistic and clinical evidence supporting natural products in IBS management, while highlighting critical gaps and future research priorities.

  • Open Access

    Integrating natural products with modern medicine in the treatment of gouty arthritis: a review

    by Sherif S. Abdel Mageed, Fatma Abdelhakim Mohamed, Marina Sobhy, Ahmed H. Elosaily, Ahmed M. El-Dessouki, Heba R. Ghaiad, Mai A. Abd-Elmawla, Mohamed I. Fahmy, Mennat-Allah M. Hassan, Riham A. El-Shiekh, et al.

    Gout is an inflammatory form of arthritis caused by hyperuricemia, a condition in which uric acid levels in the body become excessively high. When this occurs, monosodium urate (MSU) crystals can accumulate in the joints, triggering intense pain, swelling, and inflammation. If left untreated, gout can lead to joint damage and other complications. Diet is a key factor in the development and management of gout since some meals may increase uric acid levels while others can help relieve symptoms. To reduce circulating urate levels, commonly used drugs include allopurinol and febuxostat. However, the intake of these medications is associated with undesirable side effects. As a result, the development of a novel active, safe anti-hyperuricaemic and anti-inflammatory medicine could be extremely beneficial in gout treatment. Natural products have become a source of new medications because of their high efficacy and low side effects, which are based on the presence of complex bioactive components. A rising number of researchers document that traditional medications can reduce serum urate levels. This article is intended to trace which herbal remedies could alleviate hyperuricemia, as well as their mechanism of actions. Graphical abstract


  • Open Access

    Unveiling metabolome heterogeneity in three species from Coccoloba and Ruprechtia through multiple approaches of UPLC/HRMS and chemometric analysis in relation to antidiabetic, antioxidant and antiglycation activities

    by Fatma Abdelhakim Mohamed, Mohamed A. Salem, Mohammed N. A. Khalil, Ali M. El-Halawany, Amira S. El Senousy

    Background: Diabetes mellitus (DM) is a major intricate metabolic disorder, being one of the chief causes of mortality worldwide. Coccoloba and Ruprechtia are two of the most intriguing polyphenol-rich genera within the Polygonaceae family. The potential of Coccoloba uvifera, Coccoloba peltata and Ruprechtia salicifolia total extracts and fractions as antioxidant, antidiabetic and anti-glycating agents was evaluated and correlated with their chemical composition via multiple approaches of metabolic profiling. Results: All the total ethanolic extracts of plant leaves revealed remarkable antioxidant activities in terms of scavenging DPPH and ABTS radicals, as well as ferric reducing antioxidant power (FRAP). Despite having more or less comparable total phenolic and flavonoid contents, C. uvifera extract showed the highest inhibitory activity against α-glucosidase enzyme (IC50 7.985 ± 1.08 μg/mL), being more potent than acarbose (20-fold). All total extracts demonstrated moderately high anti-AGEs (> 63% inhibition) in BSA-fructose model. Among all examined fractions, C. uvifera 50% MeOH fraction exhibited the most potent antioxidant activity in DPPH, ABTS and FRAP assays (5697.33 ± 360.7, 3078.9 ± 249, 1664.02 ± 220 µM ascorbic acid equivalent/mg extract, respectively) and the highest α-glucosidase inhibitory activity (IC50 3.36 ± 1.04 μg/mL). A total of 140 compounds, belonging to different classes, were annotated in the three species via UPLC-HRMS, where flavonoids and phenolic acids represented the major classes. Multivariate and correlation analyses revealed the key phytochemicals contributing to α-glucosidase inhibition as 1-O-vanilloyl-hexoside, 1,3-O-diferuloylglycerol, drovomifoliol-O-glucopyranoside, protocatechuic acid glucoside, digalloyl glucose and coumaric acid sulphate. Conclusion: C. uvifera leaves extract and its 50% MeOH fraction had a superb potential to alleviate DM and its complications through their antioxidant, antiglycation and α-glucosidase inhibitory activities mediated by their versatile polyphenolic phytochemicals. Graphical